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 Abstract 
 Type 2 diabetes is still rapidly on the rise today, affecting 10.5% of individuals in the 
United States between the ages 45 to 64 and 18.4% of those between the ages of 65 to 74. In the 
past two decades, type 2 diabetes has doubled in all age groups. Many adults with type 2 diabetes 
experience difficulty managing their blood sugars, which can result in a range of further 
complications. One of the newest treatment options on the market today is a glucagon-like 
peptide-1 (GLP-1) receptor agonist, Bydureon. Similar to Byetta, Bydureon has a main 
ingredient of exenatide. It offers once a week dosing as opposed to twice-a-day, which may be 
more appealing to patients.  
 The purpose of this study was to examine the efficacy of a newly FDA released 
medication, Bydureon, once weekly dosage in adults with type 2 diabetes.  A descriptive, 
comparative, retrospective study of 35 patients evaluated efficacy by examining Hgb A1C and 
body mass index in adults with type 2 diabetes at baseline and 3 months after Bydureon was 
prescribed. Data were collected by a chart review of records in a primary care practice.  
 Results demonstrated a statistically significant difference between baseline to 3 month 
means in both Hgb A1C (t (34)= -3.05, p=.0044) and BMI (t (34) = -2.86, p = .0072) for patients 
using Bydureon. 
 Health care providers need to individualize the patients’ plans of care to address 
multifactorial areas of their diabetes care and provide them with an opportunity to successfully 
meet their goals. Practitioners must be knowledgeable about the treatment options available, 
including the newer GLP-1 receptor agonist, Bydureon and its efficacy for adults with type 2 
diabetes.  
  
 
Chapter One: Introduction 
 Diabetes mellitus, more commonly referred to as diabetes, is a group of clinically 
heterogeneous metabolic disorders that are commonly characterized by glucose intolerance 
resulting from a defect in either  the action and/or or secretion of insulin (Jones, Brashers, & 
Huether, 2010).  It is estimated that some 25.8 million people of all ages in the United States 
(U.S.) have diabetes, approximately 8.3 percent of the total population (National Diabetes 
Information Clearinghouse [NDIC], 2011). Of these 25.8 million, only 18.8 million people are 
diagnosed. Diabetes is the seventh leading cause of death in the U.S. and one of the major causes 
of heart disease, stroke, renal failure, non-traumatic lower-limb amputations, and blindness. It is 
estimated that by 2030, the estimated worldwide population with diabetes will increase by 60 
percent over the 2000 numbers (American Diabetes Association [ADA], 2012). This increase is 
due to the general population aging, as well as the eating and physical activity habits in the 
world, with a parallel increase in obesity (Van Dijk, et al., 2011).  
Although there is no cure for diabetes, there are a variety of clinical management 
strategies that can avoid or minimize complications, increase the survival rates, and improve 
quality of life for the individual with diabetes (American Diabetes Association [ADA], 2012). 
These strategies include patient education on management and monitoring of blood glucose 
levels, and maintaining blood glucose within the normal range. A number of antidiabetic 
medications have been developed to help individuals with type 2 diabetes achieve blood glucose 
levels. The most recent of these medications are the incretin mimetics including exenatide. 
Byetta, a twice daily subcutaneous dosage of exenatide was released by the FDA in April of 
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2005 and its use has been on the rise since then. More recently, in January 2012, Bydureon, an 
extended release dose of exenatide, was approved by the FDA (Exenatide, 2012).  
Purpose 
The purpose of this study was to examine the clinical efficacy of Bydureon, once weekly 
dosage in adults with type 2 diabetes. This descriptive, comparative, retrospective study 
evaluated medication efficacy by examining Hgb A1C and body mass index in adults with type 2 
diabetes at baseline, and then at 3 months after Bydureon was prescribed. The research question 
was: 
Do adult patients with type 2 diabetes who are started on the once weekly dosage of Bydureon 
have an improved Hgb A1C and BMI over a 3 month period?  
Theoretical Framework 
The conceptual framework that grounds this study is the health belief model, first 
developed in 1935 by Kurt Lewin, the Gestalt psychologist (Rosenstock, Strecher, & Becker, 
1988).  Lewin developed the field theory of decision making and believed that people are viewed 
as acting in a life space, which is the quantity of all the psychological factors imposing upon a 
person at any given moment in time. In the 1950s, a group of social psychologists, including 
Rosenstock, Hochbaum, and Kegels, working for the U.S. Public Health Services, focused on 
making improvements in preventative health services. They further developed the health belief 
model while trying to examine why individuals did not participate in prevention and screening 
programs. In the 1970s and 1980s, this model was expanded by Becker, and the latest changes to 
the model were done in 1988 (Rosenstock, et al., 1988).  The health belief model has been 
recommended as an applicable and appropriate model for health promotion in individuals with 
diabetes (Gutierrez & Long, 2011).  
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The health belief model addresses an individual’s perception of the risk of a health 
problem and the associated assessment of a recommended behavior for managing the problem, 
which is manifested as a behavior (Rosenstock, et al., 1988). There are three major components 
of the model: individual perceptions, modifying factors, and likelihood of action (See Figure 
1.1).  This specific conceptual framework is relevant because medication adherence is frequently 
assessed and evaluated through the lens of the health belief model. It is apparent that in 
individuals with diabetes, control is intimately linked to medication adherence, and control of the 
disease is linked to clinical outcomes, and long-term complications such as renal failure, 
amputations, diabetic ulcers, and blindness. Improving medication adherence results in tighter 
glucose control, maximizing the potential for improved outcomes.  
Figure 1.1 
 
Figure 1.1. From “Basic Elements of the Health Belief Model,” by R. Ashford and A.S. 
Blinkhorn, 1999, British Dental Journal, 186, p.436. Copyright 2012. Reprinted with 
permission. 
 
Individual Perceptions 
Individual perceptions are those perceptions of one’s susceptibility to the disease or 
condition and one’s perception of the seriousness of the disease or condition if one develops the 
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condition (Rosenstock, et al., 1988). Perceived susceptibility is one’s opinion of the chances or 
assessment of their risk for developing the condition, in this case, diabetes. In a diabetic 
individual, perceived susceptibility is determining their beliefs regarding the results of 
medication non-compliance.  
Perceived severity is one’s opinion on the severity of a condition and its potential 
consequences. In a diabetic individual, perceived severity is looking at their beliefs about the 
severity of their health illness and resulting complications.  
Modifying Factors 
 Modifying factors are demographic and psychosocial variables, perceived threat, and 
cues to action.  Demographics include the individual's age and sex, and psychosocial variables 
include the individuals personality and social class. Perceived threat is the threat of diabetes 
itself. Cues to action are factors that may be used to activate the willingness of the person and 
stimulate the good behaviors. Cues of action stimulates the individuals readiness to act on their 
given health plan or medication regimen (Kuhns & McEwen, 2011). 
Likelihood of Action 
Likelihood of action is the likelihood that the individual will take the plan of action and 
follow through with it. This last component of the health belief model includes an examination of 
the interplay between perceived benefits of and perceived barriers to the health promoting 
behavior. Perceived benefits are one’s assessment of the positive consequences of adopting the 
health behavior. In an individual with diabetes, perceived benefits are defined as the individual’s 
overall health and their perception of how the medication regimen will benefit their overall 
health (Kuhns & McEwen, 2011).  
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Perceived barriers are one’s opinion of the tangible and psychological cost of the advised 
action (Kuhns & McEwen, 2011). In an individual with diabetes, perceived barriers are the 
individual's perception of the side effects of the medications, their long term effects, and the 
difficulty of integrating the medication regimen into their daily life schedule.  
Self-efficacy defines the confidence the individual feels in their ability to successfully 
manage and maintain their health illness. It was introduced to address habitual unhealthy 
behaviors and the challenges with respect to those behaviors (Kuhns & McEwen, 2011).  
Definition of Terms 
Diabetes Mellitus 
 Diabetes mellitus is a condition characterized by hyperglycemia resulting from the 
body’s inability to utilize blood glucose for energy (Jones et al., 2010).  
Type 2 diabetes 
Type 2 diabetes is a condition characterized by high blood glucose levels or glucose 
intolerance typically presenting in adulthood and exacerbated by obesity and an inactive 
lifestyle. This condition results in either a lack of insulin secretion or the inability of the body to 
use insulin efficiently (ADA, 2012).  
Bydureon 
Bydureon is a once-a-week dosed incretin mimetic medication used to reduce fasting and 
postprandial glucose levels (Lippincott, 2012). 
Hemoglobin A1C (Hgb A1C) 
Hemoglobin A1C is a laboratory measure of an individual’s blood glucose level average 
over a period of two to three months. It is a direct measure of the amount of glucose adhering to 
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the red blood cell, which is directly proportional to the amount of glucose in the blood (ADA, 
2012). 
 
Body mass index (BMI) 
Body mass index is a calculated measure used to evaluate body weight relative to a 
person’s height and determines if a person is underweight, normal weight, overweight, or obese. 
The formula for BMI is: Weight (lb) / (Height (in) x Height (in)) x 703 (ADA, 2012).  
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Chapter Two: Review of Literature 
This chapter begins with a basic overview of diabetes mellitus. Type 1 diabetes mellitus 
is briefly discussed followed by a thorough discussion on type 2 diabetes mellitus, covering the 
pathophysiology, prevalence, risk factors, clinical manifestations, evaluation, and treatment 
including the new incretin mimetic medication, exenatide. Lastly, research on exenatide are 
examined and summarized. 
Diabetes Mellitus  
Diabetes mellitus, more commonly referred to as diabetes, is not a single disease but a 
group of clinically heterogeneous disorders that are classified by glucose intolerance (Jones, et 
al., 2010).  Diabetes consists of several different etiologies of disturbed glucose tolerance and 
includes many causally unrelated diseases. Disturbance of carbohydrates, fats, and protein 
metabolism characterizes diabetes as well as chronic hyperglycemia. There are four different 
categories of diabetes; type 1; type 2; other specific types, generally associated with medications 
and/or other conditions; and gestational diabetes, which is diabetes diagnosed in and confined to 
the pregnancy period (ADA, 2012). The most common of the four are type 1 and type 2 diabetes 
(see Table 2.1 for a general comparison).  
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Table 2.1  
 Comparison of Type 1 and Type 2 Diabetes 
Feature Type 1 Diabetes Type 2 Diabetes 
Onset Sudden Gradual 
Age at Onset Mostly young Mostly in adults 
Body Habitus Thin or normal Often obese 
Ketoacidosis Common Rare 
Autoantibodies Usually present Absent 
Endogenous insulin Low or absent Normal, decreased or increased 
Concordance in 
identical twins 
50% 90% 
Prevalence Less prevalent  90-95% of US diabetics  
From Comparison of type 1 and 2 diabetes. Information from http://www.diffen.com/ difference/ 
Type_1_Diabetes_vs_Type_2_Diabetes  
 
Type 1 Diabetes 
 
 Type 1 diabetes, previously known as juvenile diabetes or insulin-dependent diabetes, is 
the result of the absence of insulin production due to an autoimmune-mediated specific loss of 
beta cells in the pancreatic islet. A genetic-environmental interaction is thought to be the cause of 
type 1 diabetes, but it is still unclear. While diagnosed in both children and adults, diagnosis of 
the disease is most commonly made at the age of 12 years with winter and fall seasonal 
distribution.  Type 1 diabetes mellitus affects 0.17 percent of children in the United States and 10 
percent of all the people with diabetes. The staple in the pharmacologic management of type 1 
diabetes is the self-administration of insulin (Jones, et al., 2010).  
Type 2 Diabetes  
The endocrine system is a complex network made up of integrated hormone-producing 
glands and organs that produce and release various hormones to maintain and control important 
functions in the body. In the case of diabetes, this network involves insufficient islet B-cell and 
adipose-tissue responses to chronic fuel surplus, which results in a so-called nutrient spillover, 
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resistance of insulin, and finally, overall metabolic stress. The final damage includes multiple 
organs (Nolan, Damm, & Prentki, 2011).  
In type 2 diabetes, the body either fails to produce sufficient insulin to meet the body’s 
needs (decreased insulin secretion by beta cells) or insulin target cells ignore the insulin (insulin 
resistance). In order for the body to utilize glucose for energy, insulin is necessary. When an 
individual consumes food, the body breaks down all of the sugars and starches into glucose, 
which is the basic fuel for the cells in the body.  Insulin then transports glucose from the 
bloodstream into the individual cells (Jones, et al, 2010).  
Pathophysiology  
There have been several different genes identified associated with type 2 diabetes. These 
include genes that code for beta cell mass, beta cell function, proinsulin and insulin molecular 
structure, insulin receptors, hepatic synthesis of glucose, glucagon synthesis, and cellular 
responsiveness to insulin stimulation (Nolan, et al., 2011). In combination with environmental 
influences, these genetic anomalies result in type 2 diabetes. Although many individuals with 
risk factors for type 2 diabetes, such as obesity, metabolic syndrome, and hypertension are 
insulin resistant, only those with a genetic predisposition will develop diabetes mellitus. A 
suboptimal response of insulin-sensitive tissue to insulin is what defines insulin resistance. 
Abnormality of the insulin molecule, high amounts of insulin antagonists, down-regulation of the 
insulin receptor, decreased or abnormal activation of postreceptor kinases, and alteration of 
glucose transporter proteins all are mechanisms involved in the abnormalities of the insulin 
signaling pathways and contribute to insulin resistance (Jones, et al., 2010).  
Obesity, a major contributor to insulin resistance, is noted in approximately 60 to 80 
percent of individuals with type 2 diabetes. Obesity leads to an increased level of adipokines, 
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hormones produced in adipose tissue, resulting in decreased insulin sensitivity. With a decreased 
level of insulin sensitivity, there is high risk for developing type 2 diabetes. Also associated with 
obesity are increased serum free fatty acid and intracellular deposits of triglycerides and 
cholesterol, usually due to a high caloric and lipid intake. High caloric and lipid intake results in 
interference with the signaling of intracellular insulin and decreases the responses to insulin in 
the tissue, causing an alteration in the secretion of insulin within the beta cells, intra-abdominal 
adipocytes are inflammatory cytokines that further contribute to insulin resistance (Jones, et al., 
2010).  
An individual may have diabetes for many years with masking of clinical appearance due 
to compensatory hyperinsulinemia. Compensatory hyperinsulinemia is when the body 
compensates for a state of elevated insulin in the body. This is required to achieve and maintain a 
sufficient degree of glycemic control (Edelman & Henry, 2002). Beta cells begin to dysfunction, 
which then leads to an insulin activity deficiency. Beta cells go through cell exhaustion or 
undergo cell death. As this process continues, patients then begin to present with some of the 
clinical manifestations of the disease, and type 2 diabetes is then diagnosed (Jones, et al., 2010).  
When the disease has gone on unrecognized for many years, complications, such as early stages 
of microvascular and frank macrovascular disease may be present at the time of diagnosis 
(Edelman & Henry, 2002). 
Glucagon is a very important hormone in the endocrine system that is produced by the 
alpha cells of the pancreas and acts in the liver to increase blood glucose by acting as an 
antagonist to insulin. In type 2 diabetes, the pancreatic alpha cells are less responsive to glucose 
inhibition, resulting in an increased glucagon secretion, resulting in increased hepatic glucose 
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and subsequent hyperglycemia. Amylin, also released by the beta cells, inhibits functions to 
inhibit glucagon secretion (Jones, et al., 2010).  
Several peptides are involved in the processes of glucose metabolism. Incretins are 
released from the gastrointestinal tract, in response to food intake, and increases the sensitivity of 
beta cells to circulating glucose levels, thereby improving insulin responsiveness to meals. GLP-
1 is cleaved from proglucagon in the intestinal mucosa, and binds to receptors on beta cells, 
increasing the synthesis and secretion of insulin in response to glucose levels. Another peptide 
produced in the gastrointestinal tract and pancreatic islets cells is ghrelin. Ghrelin stimulates 
growth hormone production; decreased levels of ghrelin have been associated with insulin 
resistance and increased fasting insulin levels in individuals with type 2 diabetes (Jones, et al., 
2010).  
Prevalence 
Within the United States, type 2 diabetes accounts for approximately 90% of all diabetes 
cases. Type 2 diabetes is most common among Latinos, Native Americans, Asian Americans, 
African Americans, Native Hawaiians, other Pacific Islanders, and the aged population (ADA, 
2012).  
The incidence of type 2 diabetes has doubled in the past two decades. Although the 
greatest increase  has been seen among white men, type 2 diabetes diagnosis remains the most 
common among black women. There has also been an increase in diagnosis among Native 
American children aged 15 to 19 and in obese children worldwide (ADA, 2012).  
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Risk Factors  
The most well-recognized risk factors for type 2 diabetes are age, obesity, hypertension, 
physical inactivity, and family history. Other risk factors still being investigated are elevated C-
reactive protein, decreased adiponectin, increased leptin, and increased interleukin 6 (IL-6) 
(Jones, et al., 2010).   
Clinical Manifestations 
 Type 2 diabetes often has nonspecific clinical manifestations. While this disease may 
affect individuals younger than age 30 years, it typically afflicts individuals older than 30 years 
of age. Some of the classic symptoms of type 2 diabetes are polyuria, an increase in urination; 
polydipsia, an increase in thirst; and polyphagia, an increase in hunger (Edelman & Henry, 
2002). Hunger is triggered by the decrease or depletion of insulin resulting in the inability to 
transport glucose from the intravascular tissue into the cells depleting the muscles and organs of 
an energy source.  Although an individual may experience an increase in appetite in order to 
satisfy their hunger, weight loss may be noted due to the inability to metabolize glucose affecting 
utilization of alternative fuels stored in muscle and fat tissue.  
Fatigue is also a common feature experienced in type 2 diabetes.  Hyperglycemia results 
in osmotic changes not only in the vasculature but within the ocular tissue as well resulting in 
visual changes such as diminished visual acuity. Furthermore, type 2 diabetics may result in 
delayed wound healing and frequent infections such as vaginal and urinary tract infections. 
Individuals with type 2 diabetes may develop acanthosis nigricans, dark and velvety areas within 
the folds and creases of the skin, typical of insulin resistance that is caused by changes in keratin 
in the skin. The presence and severity of symptoms may vary from individual to individual or 
may be entirely absent (Jones, et al., 2010).  
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Evaluation  
Diabetes should be suspected in the presence of any of the above signs and symptoms. 
Clinicians should have a high index of suspicion of type 2 diabetes if multiple risk factors are 
present, even in the absence of signs and symptoms. These individuals should be screened for 
pre-diabetes, the condition in which an individual has either impaired fasting glucose or impaired 
glucose tolerance (Edelman & Henry, 2002).  
Laboratory evaluation may be a fasting plasma glucose, 2-hour oral glucose tolerance 
test, and HgbA1c (Jones, et. al., 2010). These tests may be used to diagnose either pre-diabetes 
or diabetes. Table 2.2 provides the laboratory differentiation between pre-diabetes and diabetes. 
Pre-diabetes may be manifested as either impaired fasting glucose or impaired glucose 
intolerance. 
Table 2.2  
 Laboratory Evaluation for Diagnosis of Diabetes 
Test Values for Pre-diabetes Values for Diagnosis 
Random Blood Glucose Two random test greater or 
equal to 140mg/dl but less 
than 200mg/dl 
Greater than or equal to 200 
mg/dl 
Fasting Plasma Glucose 100mg/dl to 125mg/dl Greater than or equal to 
126mg/dl 
2-hour post-75Gm 
Glucose Load 
140mg/dl to 199mg/dl Greater than or equal to 
200mg/dl  
Hgb A1C 5.7% to 6.4% Greater than or equal to 6.5% 
Information from “Diagnosis and Classification of Diabetes Mellitus,” by American Diabetes 
Association, 2010, Diabetes Care, 33, pp.66-67.  
 
Elevated fasting plasma glucose concentration, abnormal oral glucose tolerance test, and 
symptoms such as polyuria, polydipsia, and polyphagia are included in the criteria for the 
diagnosis of diabetes. Impaired glucose tolerance resembles diabetes mellitus in that it results 
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from reduced suppression of hepatic glucose output and a reduction in the function of the 
pancreatic islet cells. Similar to overt diabetes, individuals with impaired glucose tolerance are at 
increased risk of cardiovascular disease and premature death (Jones, et al., 2010). These 
individuals should be informed of their increased risk from their health care provider and should 
be counseled on effective strategies, such as exercise and dieting, to decrease their risks. These 
individuals should see their health care provider more frequently to have these tests completed 
and continue close monitoring of diabetes. Persons, who are diagnosed with type 2 diabetes, 
should be referred to an endocrinologist for follow up every three to six months for development 
of a plan of care prescribed by the endocrinologist (ADA, 2010).  
Treatment 
 Treatment of type 2 diabetes is a very important aspect in the overall management of type 
2 diabetes. The goal of treatment is to restore near-euglycemia and correct related metabolic 
disorders. Diet, exercise, and weight loss are an important adjunct to an appropriate medication 
regimen. While caloric restrictions are the mainstay of an appropriate diet for the type 2 diabetic, 
minimizing the consumption of refined carbohydrates including processed sugars should also be 
incorporated as part of the diabetic regimen. A potential benefit of weight loss is a reduction in 
insulin resistance and increase in insulin sensitivity further improving glucose control. Based on 
the Medical Nutrition Therapy for Prevention and Treatment of Diabetes, each diet needs to be 
individualized with a focus on reduction in fats and carbohydrates (Jones, et al., 2010).  
Exercise is a very important aspect in individuals with type 2 diabetes. Exercise promotes 
insulin sensitivity resulting in reductions in glucose levels as well as diminished medication 
requirements (Nolan, et al., 2011). In addition, exercise reduces serum triglyceride and total 
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cholesterol levels while increasing high-density lipoprotein levels, enhancing weight loss weight, 
and an overall feeling of well-being.   
 When diet and exercise are ineffective in adequately managing diabetes, the use of 
medications is indicated. Oral medications include sulfonylureas, biguandides, 
thiazolidinediones, dipeptidyl peptidease-4 inhibitors, and α-glucosidase inhibitors. 
Sulfonylureas are used to acutely supplement beta cell insulin secretion, whereas biguandides 
prevent hepatic glucose production and increase the sensitivity of peripheral tissue to insulin. 
Thiazolidinediones increase insulin sensitivity, especially in adipose tissue. DDP-IV inhibitors 
increase GLP-1 levels that in turn increase insulin secretion. a-Glycosidase inhibitors delay 
carbohydrate absorption in the gut and inhibit disaccharides and therefore decrease postprandial 
hyperglycemia (Nathan, et al., 2009).  
While traditionally reserved for use in later stages of type 2 diabetes, the early initiation 
of exogenous insulin has become more common and suggested (Nathan, et al., 2009). Insulin 
increases peripheral glucose utilization and therefore decreases hepatic glucose output and 
lipolysis.  Insulin may also be used in conjunction with various combinations of oral medications 
(Krentz, Patel, & Bailey, 2008). More recently, the discovery of the incretin system has led to the 
advent of a novel class of anti-diabetic medications known as the GLP-1 receptor agonists, 
specifically extenatide (Campbell, 2011).  
Exenatide 
 GLP-1  is an amino acid that enhances glucose-dependent insulin secretion as well as 
other antihyperglycemic functions including suppressing glucagon secretion and delaying gastric 
emptying thereby slowing carbohydrate absorption into the blood stream (Lippincott, 2012). 
Exenatide, a GLP-1 receptor agonist, is an injectable synthetic formulation of exendin-4, a 
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peptide derived from the saliva of the Gila monster. The amino acid sequence of exenatide 
partially overlaps that of GLP-1 thereby mimicking the effects of GLP-1. GLP-1 activity helps to 
improve glycemic control whenever blood glucose is elevated and in a fasting state, stimulates 
glucose-dependent insulin secretion and suppresses inappropriate glucagon secretion, which then 
decreases hepatic glucose production. In a nourished state, GLP-1 stimulates glucose-dependent 
insulin secretion, suppresses postprandial glucagon secretion, which decreases hepatic glucose 
production, improves first-phase insulin response, slows gastric emptying, and reduces food 
intake (Bydureon, 2012).  
Exenatide is contraindicated in patients with hypersensitivity to exenatide or its 
components, type 1 diabetes or diabetic ketoacidosis, and individuals with end-stage renal 
disease or severe gastrointestinal disease. While adequate studies of exenatide use during 
pregnancy are limited, rat studies did result in fetal abnormalities. Thus, exenatide is a pregnancy 
category C drug that should only be used during pregnancy if the potential benefit outweighs the 
potential fetal risk. Furthermore, exenatide should be used cautiously during breastfeeding 
(Lippincott, 2012).  
Adverse reactions to exenatide include dizziness, headaches, weakness, anorexia, 
diarrhea, dyspepsia, nausea, pancreatitis, vomiting, reflux, hypoglycemia, excessive sweating, 
prutitis, urticaria, rash, injection site reaction, angioedema, and anaphylaxis. Common drug 
interactions may include acetaminophen, digoxin, lisinopril, lovastatin, and sulfonylureas 
(Lippincott, 2012).  
 Important considerations for exenatide involve assessing renal and gastrointestinal 
function before and frequently during treatment (Exenatide, 2012). Glucose levels should be 
monitored regularly and glycosylated hemoglobin levels obtained periodically.  Exenatide should 
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be discontinued if pancreatitis is suspected. When prescribing exenatide, the patient should be 
informed of the risks of use as well as a review of the proper use and storage of dosage pen and 
pen needles. The patient should be informed as to the timing of administration of exenatide with 
respect to the morning and evening meal.  
Patients should be made aware that exenatide may decrease appetite, food intake and 
body weight and does not warrant a change in dosage. Individuals on exenatide need to be 
educated that severe, persistent, unexplained abdominal pain or vomiting needs to be reported to 
health care provider immediately. Steps for managing hypoglycemia need to be reviewed with 
individuals taking exenatide.  The storage of exenatide is very important and needs to be 
reviewed with the individual.  Patients should be educated on infection prevention of local site 
injections (Exenatide, 2012).  
Preparations 
Exenatide is available in two preparations, Byetta and Bydureon. Byetta is prepared as 5 
mcg/dose and 10 mcg/dose in 1.2 ml and 2.4 ml prefilled pens respectively.  Byetta is 
administered subcutaneously within 60 minutes before the morning and evening meals. The 
individual is usually initiated on a 5 mcg subcutaneous dose twice daily and then escalated to a 
10 mcg subcutaneous dose twice daily after one month. Byetta may be administered in the 
traditional subcutaneous sites such as the thigh, abdomen, or upper arm.  Furthermore, Byetta 
should be stored in the refrigerator at 36 to 46 degrees Fahrenheit and should be discarded after 
30 days, even if it is not completely empty (Exenatide, 2012).    
Bydureon is the newly approved extended-release formulation of exenatide. Bydureon is 
available as a single dose weekly injection of 2 mg. Bydureon is supplied as a self-contained kit 
which includes a 2 mg dose of powdered Bydureon that is then suspended in an accompanying 
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prefilled syringe of diluent before injection. This medication is administered once weekly and 
can be administered at any time during the day, with or without meals, provided it is 
administered the same day every week.  Once again, this subcutaneous injection can be given in 
the thigh, abdomen, or upper arm and should be stored in the refrigerator at 36 to 46 degrees 
Fahrenheit and discarded after 30 days, even if it is not completely empty (Bydureon, 2012).   
Research on Exenatide 
 A series of studies, called DURATION, have been completed. These studies examine the 
efficacy of Byetta and/or Bydureon and/or other hypoglycemic agents. 
DURATION-1 was a randomized, multicenter, comparator-controlled, open-label trial 
that compared Byetta versus Bydureon in 295 patients with type 2 diabetes. This study focused 
on Hgb A1C, fasting plasma glucose, and body weight. Bydureon elicited sustained 
improvements in glycemic control and body weight throughout the 52-week study, and patients 
who switched from Byetta to Bydureon experienced further improvements in Hgb A1C and 
fasting plasma glucose (Buse, et al., 2010). 
 DURATION-2 compared the efficacy and safety of Bydureon versus Sitagliptin or 
Pioglitazone as an adjunct to metformin for type 2 diabetics. This was a 26-week randomized, 
double-blinded, double-dummy, superiority trial that included 514 participants. Addition of 
Bydureon to metformin achieved the goal of optimal glucose control more than an addition of 
maximum daily doses of either Sitagliptin or Pioglitazone (Bergenstal, et al., 2010).  
DURATION-3 compared exenatide once weekly with insulin glargine in patients with 
type 2 diabetes. This study was an open-label randomized trial that included 456 patients, 233 on 
Exenatide and 223 on insulin glargine. Hgb A1C was monitored throughout this 26 week study 
and the interpretation from this study was that Bydureon is an important therapeutic option for 
19 
 
type 2 diabetics for whom risk of hypoglycemia, weight loss, and convenience are particular 
concerns (Diamant, et al., 2010).  
DURATION-4 compared the efficacy and safety of Bydureon versus metformin, 
Pioglitazone, and Sitagliptin used as monotherapy in drug-naïve type 2 diabetic patients. There 
were a total of 820 participants in this study that were monitored over 26 weeks in this double-
blind study. The results showed that Bydureon was non-inferior to metformin, but not 
Pioglitazone and was superior to Sitagliptin with regards to reduction of Hgb A1C. Bydureon 
and Metformin showed similar improvements in blood sugar control along with weight reduction 
benefit and no increased risk of hypoglycemia  (Russell-Jones, et al., 2011).  
DURATION-5 compared the effects of once-weekly Bydureon versus twice daily, Byetta 
for treatment of patients with type 2 diabetes. This study was conducted in 43 sites throughout 
the United States, with 252 type 2 diabetic participants, and it was a 24 week, randomized, open-
label, comparator-controlled study that focused on glycemic control, body weight, and safety 
with exenatide.  Hgb A1C was measured from baseline to week 24 and in conclusion, Bydureon 
resulted in superior glycemic control, with fewer side effects than Byetta did in patients with 
type 2 diabetes (Blevins, et al., 2011). 
Lastly, DURATION-6 study was the most recent study that was completed on exenatide. 
This was a 26 week open-label, multicenter clinical study that compared Bydureon to Victoza 
when administered at the maximum dosage. This study looked at Hgb A1C and results showed 
that both treatment groups demonstrated a reduction in glucose and weight loss, but this trial did 
not meet the prespecified primary endpoint that once-weekly injections of Exenatide were 
noninferior to daily injections of Victoza (Buckley, 2011). 
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Since Bydureon trials in DURATION studies have reported positive clinical outcomes, 
Bydureon dosed once a week may be more convenient and as effective as other GLP-1 receptor 
agonists. This research will provide information for the advanced practice nurse in a family care 
setting to educate patients on making decisions as to the medication regimen for managing their 
type 2 diabetes. This study determined the effectiveness of Bydureon as related to Hgb A1C and 
BMI results over a 3 months period, from a small sample in a primary care setting. This aids the 
advanced practice nurse in developing a successful treatment plan and provided knowledge on 
Bydureon effectiveness.  
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Chapter Three: Methodology  
This chapter includes a description of the research design, the sample, and setting for the 
study. Following is a discussion of the methods for data collection, tools for measurement, 
statistical analysis and the protection of human subjects.  
The purpose of this study was to examine the efficacy of Bydureon, once weekly dosage 
in adults with type 2 diabetes. This descriptive, comparative, retrospective study evaluated the 
medication efficacy by examining Hgb A1C and body mass index in adults with type 2 diabetes 
at baseline, and then 3 months after Bydureon was prescribed. The research question was: 
Do adult patients with type 2 diabetes who are started on the once weekly dosage of Bydureon 
have an improved HGB A1C and BMI after a 3 month period?  
Study Design 
A descriptive, comparative, retrospective design comparing baseline to 3 month of Hgb 
AIC and BMI was used to examine once weekly dosing of Bydureon in adults with type 2 
diabetes. Outcomes measured were Hgb A1C and BMI.  
Sample and Setting 
 Based on a power analysis, a convenience sample size of 35 patients over the age of 18 
with type 2 diabetes who were started on the newly released GLP-1 were selected for this study. 
This provided sufficient statistical power to determine large effect sizes in the two variables, Hgb 
A1C and BMI by using a paired t-test (alpha=0.05; beta=0.2). Participants were recruited from a 
local endocrinology clinic in northeast Florida. 
Inclusion criteria were males and females with type 2 diabetes who are 18 years-of-age or 
older, who have been on Bydureon for at least 90 days, with a Hgb A1C and BMI that were 
recorded in their chart before they started on Bydureon and then 3 months after treatment was 
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started. Exclusion criteria were any male or female with type 1 diabetes, any individual being 
treated with insulin other than basal and brief course of short-acting insulin.  
It was unknown in this study if these patients were newly diagnosed with type 2 diabetes, 
the type 2 diabetes diagnosis date, and the exact reason why Bydureon was the medication of 
choice for the particular participant.  
Recruitment 
 Every clinical medical record where Bydureon was prescribed was reviewed for 
inclusion and exclusion criteria. The physician and/or nurse practitioner at this individual clinic 
advised the primary investigator when they ordered Bydureon for a patient and data collection 
began with chart review to determine if they met both inclusion and exclusion criteria. If they 
met both inclusion and exclusion criteria, then data collection began with a chart review. IRB 
reviewed the study, it was deemed exempt. As this was a retrospective chart review, individual 
consent was not necessary.  
Procedures 
 Demographic data, information about use of Bydureon, and laboratory and 
anthropological measurements were gathered. Demographic data included date of birth, gender, 
and date Bydureon was started. All data was gathered and placed into a flow chart.  
Retrospective chart review provided the laboratory data (Hgb A1C) and anthropological 
measurements (height and weight). BMI was calculated based on the patient’s height and weight. 
The location where the patient had their labs drawn for their Hgb A1C varied depending on their 
insurance. The clinic has a contract with some insurance companies to draw labs in the office 
and others were sent out to have their labs drawn, however, these details were not obtained on 
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the individual participants. If labs were drawn outside of the clinic, the results were sent to the 
clinic and then inserted into their computerized chart.  
Data Collection 
Data collection for this study was a retrospective medical chart review for the clinical 
quantitative outcomes. When starting the initial data collection, the patient’s medical records 
were reviewed by the investigator, retrospectively. Data were collected on a flow chart and kept 
in a secure location without patient identifiers. A baseline Hgb A1C and BMI, as defined above 
was calculated from weight and height measurements from the initial visit when the medication 
was prescribed by the health care provider. Serial data was further obtained from records of the 
patient’s at 3 month follow up visits after being started on Bydureon. These clinical outcomes 
were also documented in a computerized spreadsheet by the investigator. Patients were 
numbered one through thirty five.  
Statistical Analysis Plan 
Descriptive statistics were used to characterize the sample with respect to the lab and 
demographic variables related to Bydureon use. A distribution analysis and change analysis were 
performed and looked at age, baseline BMI, 3 month BMI, baseline Hgb A1C, and 3 month Hgb 
A1C. A paired t-test was used to determine if there was a difference in before starting on 
Bydureon and after 3 months of being on Bydureon, for both Hgb A1C and BMI.  
Protection of Human Subjects 
Data collected were held confidential and no names or personal information were 
disclosed. Approval from the University of North Florida Institutional Review Board was 
obtained prior to undertaking the study (see Appendix A). The study was deemed exempt by the 
UNF IRB. When collecting Hgb A1C and BMI data, the medical record was identified by only a 
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number and initials on a spreadsheet. Data were kept in a spreadsheet on a password coded 
computer accessible only to the investigator.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
Chapter Four: Results 
This chapter includes the statistical findings of this study. Demographic information is 
first summarized. Following the demographic information, inferential statistics of the study are 
presented.  
As mentioned in chapter three, the purpose of this study was to examine the efficacy of 
Bydureon, once weekly dosage in adults with type 2 diabetes. This descriptive, comparative, 
retrospective study evaluated the effects of Bydureon by examining Hgb A1C and BMI in adults 
with type 2 diabetes at baseline and then again 3 months after Bydureon is started. Participants 
were from a local endocrinology clinic in northeast Florida. The retrospective chart reviews were 
completed in 2013 at Northeast Florida Endocrine and Diabetes clinic in Jacksonville, Florida.  
Characteristics of the Sample 
Participants were 33 to 84 years old. All participants had been diagnosed with type 2 
diabetes for at least 90 days but the exact duration of diabetes was not obtained. There were 17 
males and 18 females that participated in this study, for a total of 35 participants.  Demographic 
data that was obtained was gender and age and is summarized in Table 4.1. 
Descriptive Data Analysis 
Lab data collected was BMI, baseline and at 3 months, and Hgb A1C, baseline and at 3 
months. The BMI ranged from 21.58kg to 60.82kg at baseline and 21.48kg to 60.80kg at 3 
months. The Hgb A1C ranged from 5.7 to 14.0 at baseline and 5.5 to 12.2 at 3 months (see 
Appendix B). All but 7 subjects had a decrease in BMI. All but 7 subjects had a decrease in Hgb 
A1C (see Table 4.3).  Only one subject had an increase in both BMI and Hgb A1C at 3 months 
after starting Bydureon. Only one subject dropped a whole category, from obese class I to 
overweight. One patient was an outlier, and was classified as not overweight and had a normal 
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BMI at baseline and 3 months. Three subjects Hgb A1C changed from high (>6.5%) to normal 
(<6.5%) (see Table 4.2). 
Table 4.1  
 
Description of the Sample (n=35) 
 
Characteristics N % 
Gender   
         Female  18 51.4 
         Male  17 48.6 
Age   
        30-39 2 5.71 
        40-49 7 20 
        50-59 12 34.28 
        60-69 10 28.57 
        70-79 3 8.57 
        80-89 1 2.85 
 
Table 4.2  
 
Description of Baseline Variables (n=35) 
 
Baseline Variables N % 
Hgb A1C     
         < 6.5%  8 23 
         > or = 6.5%  27 77 
BMI     
        Not overweight  1 3 
        Overweight 8 23 
        Obese Class I 12 34 
        Obese Class II 10 29 
        Obese Class III 4 11 
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Table 4.3  
 
Hgb A1C Change (baseline to 3 months) (n=35) 
 
Hgb A1C Change (baseline to 3 months) N        % 
Hgb A1C     
         High to normal 3 9 
         Same (high or normal, without worsen) 25 71 
         Normal to High  0 0 
         Worsened  7 20 
 
 A distribution analysis was completed to determine the distributions of age, baseline 
BMI, 3 month BMI, baseline Hgb A1C, and 3 month Hgb A1C. A change analysis was 
performed to determine the change from baseline to 3 months in both the BMI and Hgb A1C.  
Figure 4.1 
 
Figure 4.1.Age distribution of the participants from the study. Total of 35 participants. The 
Average age was 56.6. Standard deviation was 10.07. Developed by Dr. Peter Wludyka, 
Statistician.  
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Table 4.4 
 
Descriptive Statistics BMI and Hgb A1C(n=35) 
 
 M(SD)  M(SD)  
BMI 
Baseline 
3 Months 
Change 
 
34.89(8.16) 
34.52 (8.01) 
-0.37(0.77) 
Hgb A1C 
Baseline 
3 Months 
Change 
 
7.65 (1.61) 
7.27(1.42) 
-0.37(0.72) 
 
 
 Based on the distribution analysis and the analysis of change, the mean baseline BMI was 
34.89. The mean 3 month BMI was 34.52. The change was a decrease of 0.37 in BMI from 
baseline to 3 months after being on Bydureon. Anyone with a BMI greater than 30 is considered 
obese. Both mean baseline and 3 month BMI are categorized as obesity class I according to the 
Center for Disease Control and Prevention. Class I obesity is BMI 30 to 34.9. (CDC, 2014). The 
mean baseline Hgb A1C was 7.65. The mean 3 month Hgb A1C was 7.27. The change was a 
decrease of 0.37 in Hgb A1C from baseline to 3 months after being on Bydureon. (See Table 
4.4). Both mean baseline and 3 months Hgb A1C are classified as high. The goal for a patient 
with type 2 diabetes is a Hgb A1C less than 6.5%, according the American Association of 
Clinical Endocrinologists and American College of Endocrinology (Handelsman et al., 2011).   
Inferential Data Analysis 
Paired t-tests 
 
 A paired t-test determines whether a sample of matched pairs of similar units differ from 
each other in a significant way under the assumption that the paired differences are independent 
and identically normally distributed. In this study, by comparing the same patients BMI and Hgb 
A1C at baseline and 3 months into their Bydureon treatment, each patient was used as their own 
control. There was no other control group used for this study. With a paired t-test, the statistical 
power increases just because the random between-patient variation has been eliminated. The 
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paired t-test shows statistical significance between baseline to 3 months in both BMI and Hgb 
A1C on patients that are taking Bydureon. See Table 4.5 for paired t-test results for both BMI 
and Hgb A1C.  
Table 4.5 
Paired T-test results: Difference baseline to 3 months (BMI and Hgb A1C) 
Note. t=paired t test.  
Research Question 
The research question was: 
Do patients who are started on the once weekly dosage of Bydureon have an improved 
Hgb A1C and BMI over a 3 month period?  
Summary 
 After reviewing all of the descriptive and inferential statistical analysis it can be 
concluded that there is a difference in the means of BMI and Hgb A1C over a 3 months period 
for those on Bydureon. The results were statistically significant and this study showed that the 
participants had a decrease in both BMI and Hgb A1C over a 3 months period while taking 
Bydureon.  
 
 
 
 
 Baseline M(SD) 3 month M(SD) t(DF) p 
BMI 34.89(8.16) 34.52(8.01) -2.86(34) 0.0072 
Hgb A1C 7.64(1.61) 7.27(1.42) -3.05(34) 0.0044 
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Chapter Five: Discussion 
This chapter provides a discussion of the results regarding BMI and Hgb A1C at 
baseline and at 3 months in adults with type 2 diabetes after starting on the newer GLP-1 
receptor agonist, Bydureon. Following this discussion, the limitations of the study will be 
examined. After the limitations of the study, the implications for practice and recommendations 
for future research will be provided. 
Discussion 
Results from this study do show a reduction in Hgb A1C and BMI in the majority of 
patients that were taking Bydureon, after only three months of weekly doses. This indicates that 
the medication has a positive effect on adult patients with type 2 diabetes.  When compared to 
other studies that have been done on Bydureon, the results to this study are very similar. The 
DURATION-1 study was a three year study that showed patients receiving Bydureon 
experienced a significant reduction in Hgb A1C (1.6 percentage points) and weight (5.1 pounds) 
when compared to baseline (Buse, et al., 2010). With a longer duration to follow the participants 
in this research study on the efficacy of Bydureon, it would be expected to have greater 
outcomes like the DURATION-1 study. Compared to Lantus, the DURATION-3 study showed 
that at 84 weeks, patients treated with Bydureon experience a significantly greater Hgb A1C 
reduction from baseline as well as a weight loss while taking the medication versus the patients 
that were on Lantus experienced a weight gain (Diamant, et al, 2010). This again is similar to 
the results that were found in this study, when looking at Bydureon independently.  
This study is clinically significant because there are a large number of individuals today 
with type 2 diabetes. With the number of patients with type 2 diabetes on the rise, health care 
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providers can use this information, knowing that this medication decreases Hgb A1C and BMI, 
and use it when trying to find the appropriate diabetes treatment regimen for their patients.  
Limitations 
 Although the study showed significant differences between HgbA1C and BMI when 
taking Bydureon, several potential limitations warrant mention. Some of the limitations in this 
study were medications, lifestyle, medical history and number of participants.  
Medications 
 This study could have been improved if the patient’s complete medication list was 
reviewed prior to accepting them to participate in the study. Certain medications that could have 
had an impact on the participant’s results were medications such as weight loss medications, 
steroids, and other diabetic medications. If a participant was taking a weight loss medication, the 
results of the BMI would be not a good reflection as to the improvements of weight loss from 
Bydureon alone. Another thing that could have been taken into consideration in this study was 
compliance and adherence to therapy and/or proper use of medication, as this was not studied.  
Lifestyle 
 This study could have been improved if patients’ lifestyles were taken into 
consideration. Patients’ BMI and HgbA1C are both impacted greatly in their day to day living 
and habits. Healthy eating habits and daily exercise may help to decrease or control patient’s 
BMI and HgbA1C, as well many of the complications that are associated with type 2 diabetes. 
Also, an individual’s level of stress could impact their BMI. Had all of these components been 
assessed during this study, more accurate results could have been produced.  
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Medical history 
The only thing reviewed in the participants medical history was their diagnosis of type 2 
diabetes. The date of type 2 diabetes diagnosis would have been beneficial to document on each 
participants. A thorough medical history review to improve this study would have been 
beneficial. Medical conditions that may have affected the results are history of bariatric surgery, 
certain cancers, particularly pancreatic cancer and chronic GI complications.  
Participant Number 
 Based on a power analysis, the minimum number of subjects I needed for this particular 
study was 35 and the number of subjects was 35. With a larger sample size, there would have 
been a stronger power, and therefore, more conclusive results with this study on the efficacy of 
Bydureon.  
Implications for Practice 
 It appears that Bydureon does have a positive effect on both Hgb A1C and BMI after 
only three months. This is consistent with the research that compares this medication to other 
medications on the market today. As practitioners, it is imperative that treatment of type 2 
diabetes is not pharmaceuticals alone. Patients should be educated on healthy eating habits and 
healthy doses of exercise because from the research that was done as well as other research on 
type 2 diabetes, it is apparent that patients with type 2 diabetes are typically overweight or 
obese.  During dietary counseling, encouraging the patient to minimize carbohydrates would be 
a helpful step in managing their type 2 diabetes. Patients need to be educated that their diabetes 
medication is based on the amount of carbohydrates at each meal, therefore if the individual eats 
more carbohydrates than they should, the diabetes medication will not be as effective and 
therefore blood sugars may be uncontrolled. Creating your plate and being mindful of what you 
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eat is a good step forward when trying to manage your blood sugars. Encouraging these patients 
to keep a dietary log and record their meals would be a good way for patients to be more 
mindful of what they are consuming as well as be able to share with their practitioners during 
their visit in the clinic.  Portion control would be vital to discuss with patients that have type 2 
diabetes and are overweight or obese as well. The amount of food one eats is closely related to 
their blood sugar control. Measuring foods would be important to review with patients with type 
2 diabetes in order to manage portion control. If the patient is trying to lose weight and manage 
their diabetes, as a practitioner, Bydureon may be a good selection for their diabetes 
management. Twenty eight out of the thirty five participants in this study had a decrease in BMI 
during a three month period after starting on Bydureon. The study does not reveal why the other 
seven participants did not have a decrease in BMI. Twenty eight out of thirty five participants 
also had a decrease in Hgb A1C in three months on Bydureon. The study does not reveal why 
the other seven participants did not have a decrease in Hgb A1C. Compliance and medical 
conditions would be worth looking into with these select participants that did not successfully 
progress in their treatment as research has demonstrated in the past.  
Bydureon is administered as a subcutaneous injection. With this being known, ease of 
use is very important for practitioners to be aware of. Like similar medications for diabetes, for 
example DPP-4 inhibitors, that are administered orally, the only route for Bydureon is via 
subcutaneous injection. It is the practitioners’ responsibility to make sure the patient is 
comfortable with administration of the medication. Bydureon is only administered once weekly, 
unlike a patient taking oral form of medication for diabetes is responsible for taking it daily and 
sometimes twice daily. Compared to the twice daily Byetta, Bydureon can be administered at 
any time of the day and does not need to be administered with meals. Byetta is a pre-filled pen 
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device and Bydureon is more complicated with a system that requires assembly. Practitioners 
prescribing Bydureon must take this into consideration because people with vision problems or 
limited manual dexterity may find Bydureon system difficult to assemble.  
Future Research 
 In view of the complexity of type 2 diabetes and the current treatment regimens 
available, more research needs to be done regarding appropriate treatment for individual 
patients. This study can benefit patients with type 2 diabetes, as Bydureon is another treatment 
option for available and this study provides some basic knowledge on the short-term 
effectiveness of this medication. Future research that would be beneficial would be a study on 
the ease of use of Bydureon to determine if patients are able to properly use the medication and 
their comfort levels with the once weekly injection. This could be concluded by return 
demonstration and personal surveys. Some information that would be beneficial to know 
regarding ease of use would be if the patient had ever administered a subcutaneous injection 
before, the patients feelings regarding preparation of Bydureon vial and syringe, do they 
administer injection themselves and if so, ease of administering injection to self, how compliant 
they are with administering their once weekly injection, have they ever missed doses, how they 
learned how to administer their first Bydureon injection and any concerns or suggestions they 
have regarding Bydureon injections. Incorporating patient’s lifestyle would be beneficial in 
future Bydureon research since eating habits and exercise are a huge part of diabetes 
management. Patients could be educated on health eating habits and exercise by their provider 
and then be required to log their daily eating habits and exercise for the duration of the study 
while they are taking Bydureon. Further research that would be beneficial in health care today 
would be looking at patients on Bydureon with different medical conditions; such as HTN or 
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hyperlipidemia and determine if the effectiveness of the medication with individuals with these 
commonly diagnosed medical conditions. A multivariate study would be imperative to future 
research by looking at more than one outcome, such as incorporating age, gender, and even 
ethnicity to determine if they are statistically significantly in the outcome of patients taking 
Bydureon.  
Conclusion 
 Today, approximately 8.3% of the population in the United States have been diagnosed 
with diabetes and that number is on the rise. The International Diabetes Federation Diabetes 
Atlas is expecting the total number of individuals with type 2 diabetes to rise to 552 million by 
2030 (Hilaire & Woods, 2013). Health care providers need to individualize the patients’ plans of 
care to address multifactorials areas of their diabetes care and provide them with an opportunity 
to successfully meet their goals. Practitioners must be knowledgeable about the treatment options 
available, including the newer GLP-1 receptor agonist, Bydureon and its efficacy for adults with 
type 2 diabetes. Based on the research question, patients started on weekly dosage of Bydureon 
do have a statistically significant improvement in Hgb A1C and BMI over a 3 month period.  
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Appendix B 
Data collection table: 
#/ 
Inital
s 
Type 2 
Diabetic 
Age/Ge
nder 
Bydureon 
Start Date 
Baselin
e BMI 
3 
month 
BMI 
Baseline 
Hgb A1C 
3 month 
Hgb A1C 
1-S.L. Yes 50/Male 5/20/2013 27.38kg
/m2 
27.47kg
/m2 
9.1 8.8 
2-A.R. Yes 36/Fema
le 
7/17/2012 28.9kg/
m2 
28.9kg/
m2 
5.9 5.8 
3-
D.M. 
Yes 48/femal
e 
10/29/2012 43.26kg
/m2 
42.47kg
/m2 
8.3 7.7 
4-
C.W. 
Yes 48/Male 2/4/2013 46.51kg
/m2 
43.11kg
/m2 
8.3 8.5 
5-
K.Q. 
Yes 47/Fema
le 
11/2/2012 36.56kg
/m2 
36.43kg
/m2 
5.8 5.7 
6-
D.W. 
Yes 51/Male 4/3/2013 33.41kg
/m2 
32.9kg/
m2 
6 6.1 
7-J.R. Yes 59/Fema
le 
10/16/2012 36.21kg
/m2 
35.08kg
/m2 
8 8.2 
8-
R.G. 
Yes 61/Fema
le 
6/19/2012 28.87kg
/m2 
27.7kg/
m2 
6.7 6.2 
9-
G.A. 
Yes 57/Male 3/21/2013 60.14kg
/m2 
59.95kg
/m2 
7.3 6.2 
10-
L.B. 
Yes 46/Fema
le 
11/26/2012 34.51kg
/m2 
33.83kg
/m2 
7.5 7.2 
11-
T.C. 
Yes 63/Male 4/11/2013 28.5kg/
m2 
28.28kg
/m2 
11.1 9.5 
12-
D.G. 
Yes 48/Male 4/1/2013 28.35kg
/m2 
28.2kg/
m2 
8.4 6.9 
13-
V.M. 
Yes 55/Fema
le 
2/1/2013 30.79kg
/m2 
29.96kg
/m2 
6.3 5.9 
14-
R.M. 
Yes 65/Male 1/17/2013 32.69kg
/m2 
33.38kg
/m2 
6 6.3 
15-
S.R. 
Yes 57/Fema
le 
9/7/2012 25.45kg
/m2 
24.84kg
/m2 
6 5.8 
16-
V.S. 
Yes 66/Fema
le 
11/19/2012 31.46kg
/m2 
32.3kg/
m2 
5.7 5.5 
17-
H.S. 
Yes 84/Fema
le 
1/4/2013 30.71kg
/m2 
30.31kg
/m2 
6.7 6.5 
18-
K.K. 
Yes 63/Fema
le 
4/5/2012 36.48kg
/m2 
36.8kg/
m2 
7.2 6.5 
19-
E.B. 
Yes 61/Male 3/12/2013 21.58kg
/m2 
21.48kg
/m2 
14 12.2 
20- Yes 55/Male 3/4/2013 29.41kg 29.41kg 7.9 8 
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S.P. /m2 /m2 
21-
C.B. 
Yes 49/Fema
le 
2/26/2013 38.77kg
/m2 
38.49kg
/m2 
7.2 7 
22-
M.C. 
Yes 71/Male 3/7/2013 60.82kg
/m2 
60.80kg
/m2 
6.7 6.5 
23-
B.W. 
Yes 59/Male 2/26/2013 33.51kg
/m2 
33.25kg
/m2 
7.2 6.9 
24-
J.W. 
Yes 60/Fema
le 
3/7/2012 35.61kg
/m2 
34.19kg
/m2 
7.6 6.4 
25-
C.F. 
Yes 59/Fema
le 
1/9/2013 38.09kg
/m2 
37.73kg
/m2 
7.6 9.7 
26-
W.M. 
Yes 60/Fema
le 
10/31/2012 32.12kg
/m2 
32.12kg
/m2 
8.1 7.2 
27-
A.L. 
Yes 62/Fema
le 
11/5/2012 31.64kg
/m2 
32.42kg
/m2 
9.2 8.9 
28-
R.R. 
Yes 33/Male 8/21/2012 31.06kg
/m2 
31.33kg
/m2 
7.6 7.6 
29-
H.H. 
Yes 70/Male 3/19/2012 38.74kg
/m2 
38.6kg/
m2 
8.9 7 
30-
D.L. 
Yes 62/Male 2/14/2013 29.95kg
/m2 
29.79kg
/m2 
6.9 6.7 
31-
J.M. 
Yes 70/Male 10/16/2012 31.53kg
/m2 
30.89kg
/m2 
6.2 5.5 
32-
V.B. 
Yes 54/Male 11/2/2012 36.93kg
/m2 
36.48kg
/m2 
7.4 7.2 
33-
H.R. 
Yes 43/Fema
le 
10/4/2012 31.41kg
/m2 
31.41kg
/m2 
8.4 8 
34-
F.B. 
Yes 53/Male 11/2/2012 40.02kg
/m2 
39.82kg
/m2 
7.6 7.9 
35-
S.G. 
Yes 56/Fema
le 
2/26/2013 39.89kg
/m2 
38.12kg
/m2 
8.8 8.6 
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Appendix C 
Acceptance letter from Dr. Segal at Northeast Florida Endocrine and Diabetes Associates, 
P.A. 
August 10, 2013 
 
         
Scott A. Segel, M.D., F.A.C.E. 
Northeast Florida Endocrine and Diabetes Associates, P.A. 
3550 University Blvd. Suite 301 
Jacksonville, Florida 32216 
Phone #: (904) 384-2240 
 
 
Dear University of North Florida Institutional Review Board, 
I am granting permission to Katie Fetter, RN, BSN, (University of North Florida- 
Family Nurse Practitioner student), to complete her research study at my medical 
practice.  I understand that her research study, Efficacy of Bydureon in Type 2 
Diabetic Patients, must first be approved by the University of North Florida IRB.  
Ms. Fetter will have access to patients and to their clinical data for her 
retrospective chart review. Informed consent is not needed for this study. 
Please do not hesitate to contact me if you have any questions or concerns. 
 
Sincerely,  
 
 
Scott A. Segel, M.D., F.A.C.E. 
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